A Novel Process for Developing Fully Human Monoclonal Antibodies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Novel Process for Developing Fully Human Monoclonal Antibodies
The authors describe a process for generating high affinity, fully human antibodies in culture. Specially selected splenocytes are incubated with cytokines and low levels of antigen, yielding affinity-matured, class-switched B cells. The fully human, specific antibodies produced by these cells can then be cloned and expressed for further characterization.


Pharmaceutical Technology
pp. s28-s31

NeoAb approach to therapeutic antibodies

Neoclone's hu-mAb platform (which has been marketed under the NeoAb process) offers certain advantages:

  • The mAbs are fully human, having been developed from human immune cells.
  • The approach does not require immunizing patients or access to convalescent blood, therefore, the platform is amenable for mAb development using de novo immunization against any therapeutic target.
  • mAbs developed using this approach will likely have higher affinities than Abs generated by library-based methods because reactivation focuses on selection of affinity-matured cell targets that proliferate in very low Ag levels.
  • hu-mAbs generated using the NeoAb process can have fully-human glycosylation patterns, a distinct advantage over human mAbs expressed in non-human cells (18).
  • The process enables selection for or against certain secondary characteristics such as Ab-dependent cellular cytotoxicity or complement-dependent cytotoxicity (19).

The NeoClone human mAb process can be divided into four stages: immunization, reactivation, cloning, and expression (see Figure 1).

Immunization: de novo immunization of human peripheral blood lymphocytes (PBL) in a SCID mouse model. NeoClone's current protocols for generating a human immune response to targeted antigens are based on published SCID-huPBL engraftment models (20–25) coupled with modifications of Ag-pulsed dendritic cell (DC) immunizations and multimer-linked Ag complex immunizations. The SCID-huPBL model repopulates immune deficient mice with human peripheral blood lymphocytes. SCID mice cannot make mature, antigen-specific B and T cells. Engraftment of human PBLs repopulates secondary lymphoid organs such as lymph nodes and spleen with human immune cells. Because of the enrichment process used, cells recovered from the immunized SCID-huPBL mouse are human, and the Ig genes cloned out from these cells are therefore fully human (20, 21, 24). All antigens are assayed for optimal concentration using a NanoDrop 8000 spectrophotometer (Thermo Scientific) before immunization. Antigen integrity and concentration are confirmed by gel electrophoresis and densitometry. Antigens are required to pass quality control by all three methods before they are formulated for immunization.

Reactivation: B cell culture and affinity screening. Activated B cells are enriched from the spleen and lymph nodes of immunized SCID-huPBL mice and then B cells are cultured in vitro with a mixture of cytokines. Antigen supernatants from the cultured B cells are tested for affinity and specificity using an Octet QK (ForteBio) which uses BioLayer interferometry to determine affinity binding constants (KD) of purified Abs, as well as rank-order crude tissue culture supernatants by Kd estimates (26). Antigens are biotinylated and immobilized on a streptavidin Octet sensor using attachment methods recommended by the manufacturer (27). Reactivated culture supernatants are rank-ordered by affinity using crude supernatant samples. Generally, affinities from 10-9 to 10-11 M are considered an acceptable affinity range. Harvested cell cultures are then subjected to fluorescence activated cell sorting (FACS) analysis in which single B cells specific for the immunizing antigen are deposited in one cell per spot on a 48-spot AmpliGrid glass slide (Beckman).


Figure 2: Screenshot from a NanoDrop 8000 showing concentration and purity measurements of paired antibody heavy and light chain constructs cloned from single cells to be used for transient transfection.
Cloning: recovery of Ig heavy and light chains, cloning, and sequencing. Single-cell reverse transcriptase-polymerase chain reaction (RT-PCR) is performed on an AmpliGrid system (Beckman Coulter) to capture the matched Ig heavy and light chain pairs from sorted cells. Ig heavy and light chains are cloned into antibody expression vectors and sequenced (see Figure 2).

Expression: protein expression and scale up. A NanoDrop 8000 spectrophotometer is used to quantitate purified preps of candidate hu-mAbs. Midiprep DNAs of paired Ig heavy and light chains cloned into antibody expression vectors are co-transfected into non-adherent mammalian cells using the TransIT reagent (Mirus Bio). Supernatants are screened for affinity and specificity as described above. Larger scale transfections can be performed on candidate hu-mAbs. Hu-mAbs can be purified by standard protocols and quantitated using the NanoDrop 8000 spectrophotometer for concentration and purity. Affinity constant (KD) determinations can be performed on purified antibodies. Additional assays to identify desired hu-mAb characteristics will be performed prior to stable cell line generation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here